(EMAILWIRE.COM, November 19, 2009 ) Point Roberts, WA – Chartpoppers.com announces an investment report featuring company Pfizer Inc. (NYSE:PFE)
Pfizer Inc. is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals
Recent News on Pfizer Inc. (NYSE:PFE)
Pfizer Inc’s (PFE.N) newer version of the Prevnar pneumococcus vaccine, the most important experimental product the company acquired from Wyeth, won support from U.S. advisers on Wednesday.
A Food and Drug Administration advisory committee voted 10-1 that Prevnar 13 was safe and effective for giving to infants and toddlers to prevent infection with bacteria that cause pneumonia, meningitis and other illnesses.
The FDA usually approves products that win support from advisory panels. A decision on Prevnar 13 is due by Dec. 30.
The vaccine is designed to fight 13 forms of a bacterium called streptococcus pneumoniae, or pneumococcus. The older Prevnar targets seven forms.
The original Prevnar was introduced in 2000 and has annual sales around $3 billion.
To view the Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) Please visit the stock pulse page at http://www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at http://www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at http://www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Chartpoppers.com
Paul Marek
6047245332
info@chartpoppers.com
Source: EmailWire.Com
Chartpoppers.com releases Investment overview on Pfizer Inc. (CHARTPOPPERS.COM, February 19, 2010 ) The Consolidated investment Analysis on Pfizer Inc. (NYSE:PFE) will be in particular interest to other competing companys within in its sector, such as Bristol... |
Medicines Agency gives go-ahead for new Pfizer logistic concept in Denmark Weinheim, 4th August 2009 – trans-o-flex Logistik-Service GmbH, a company of the trans-o-flex Logistics Group, has developed a new concept for the American pharmaceutical company Pfizer with respect... |
Paladin Labs and Pfizer Amend Canadian Estring(R) Agreement MONTREAL, QUEBEC -- (Marketwire) -- 10/15/09 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company and Pfizer Canada Inc. announced today an agreement by which they will... |
Pfizer, Kano State Reach Settlement Of Trovan Cases Pfizer Inc today announced it has reached agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study, which was conducted during Nigeria’s... |
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine)* in patients with Huntington disease. The... |
Pfizer’s Selzentry Poised To Be Most Expensive First-Line AIDS Drug Responding to today’s news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.'s AIDS therapy, Selzentry (maraviroc), for use in therapy-naïve patients,... |
